Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections

• Status: Unknown status
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical HPV-16 and/or HPV-18 infections; to analyze the HPV type infections and clinical negative conversion.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lee's Pharmaceutical Limited
• Treatments: Interferons

Criteria

Inclusion Criteria:

• Age 25 to 65 years of age with the sex life of female patients;

• HPV DNA typing test for HPV-16 and/ or HPV-18 positive in 1 month.

Exclusion Criteria:

• Patients with cervical intraepithelial neoplasia Ⅱ / Ⅲ, cervical cancer;

• Associated with fungal vaginitis, trichomonas vaginitis, HIV positive patients;

• Associated with acute, severe bacterial or viral infection;

• Autoimmune diseases;

• Within 3 months before screening patients used corticosteroids, immunosuppressants or other antiviral drugs;

• Allergies or allergy to the drug known ingredients;

• History of suffering CNS diseases, epilepsy and/or psychological disorder;

• Pregnant and lactating women;

• The researchers do not consider it appropriate clinical trials.